Michael Chiorean

Congratulations to my brilliant and most influential birthday sister #MillieLong for her well-deserved Sherman Prize! You changed not just the world of #IBD but also the lives of countless patients and young physicians who were cared for and inspired by you #BornToBeaChamp #AIBD2024

10.12.2024 22:26 — 👍 6    🔁 0    💬 0    📌 0

Included in non-aTNF biologics

10.12.2024 13:51 — 👍 0    🔁 0    💬 0    📌 0

Great clinical practice pearls for the management of ICI (immune-mediated enterocolitis) from #DrHansHerfharth: scope early to assess disease severity; use the ICI score to predict the need for advanced therapy; monitor frequently; may resume ICI when in remission #AIBD2024

10.12.2024 13:50 — 👍 2    🔁 1    💬 1    📌 0

Excellent overview on personalized #IBD therapy for #crohnsdisease complications by @MRegueiroMD at #AIBD2024. Take home point: failure of medical therapy is an adverse event that could be serious!

09.12.2024 14:34 — 👍 6    🔁 3    💬 1    📌 0

Very nice synopsis on positioning therapies for the management of luminal #crohnsdisease #IBD by @UmaMahadevanIBD at the Advances in IBD #AIBD2024

09.12.2024 14:21 — 👍 3    🔁 2    💬 1    📌 0

I am part of that study 😊; that's why I was asking... It's a difficult endpoint but, I agree with you, technology is evolving

20.11.2024 00:10 — 👍 0    🔁 0    💬 0    📌 0

Factors Associated With Biologic Therapy After Ileal Pouch-Anal Anastomosis in Patients With Ulcerative Colitis - PubMed Several demographic, disease-related, surgery-related, and genetic factors associated with post-IPAA biologic therapy were identified. Physicians treating patients with UC undergoing colectomy should ...

Very interesting and important work from a referral #IBD center. 25% of patients who had proctocolectomy w IPAA for UC required ADT after surgery; refractory UC #colitis associated w⬆️risk (HR 6.1). IPAA for UC-neoplasia did not require advanced therapy pubmed.ncbi.nlm.nih.gov/39540419/

20.11.2024 00:08 — 👍 2    🔁 0    💬 0    📌 0

1. How do you measure it as a trial endpoint?

2. More importantly,,, so?... (what is the incremental impact on disease/patient outcomes?)

17.11.2024 01:57 — 👍 0    🔁 0    💬 1    📌 0

Always great to listen to one of the #IBD masters #DrUriKupylov talking about choice of therapy in #IBD, #ColentinaGastroMarathon 2024

16.11.2024 09:16 — 👍 0    🔁 0    💬 0    📌 0